Lipoprotein apheresis--more than just cholesterol reduction?

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Atherosclerosis Supplements

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.atherosclerosissup.2012.10.017PMID 23357137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The enemy within: endogenous retroelements and autoimmune disease

  2014cited by this paper
• Current view: indications for extracorporeal lipid apheresis treatment

  2012cited by this paper
• Impact of Lipid Apheresis on Egr‐1, c‐Jun, c‐Fos, and Hsp70 Gene Expression in White Blood Cells

  2011cited by this paper
• The autoimmune concept of atherosclerosis

  2011cited by this paper
• Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

  2009cited by this paper
• Clinical outcomes and mechanism of action for rheopheresis treatment of age‐related macular degeneration (AMD)

  2005cited by this paper
• LDL‐apheresis improves peripheral arterial occlusive disease with an implication for anti‐inflammatory effects

  2005cited by this paper
• Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins.

  2005cited by this paper
• C-reactive protein levels and outcomes after statin therapy.

  2005cited by this paper
• The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst.

  2005cited by this paper
• Internet-based quality assurance registry for LDL apheresis QUASA--the apheresis registry.

  2005cited by this paper
• State of the Art of Low‐density Lipoprotein Apheresis in the Year 2003

  2004cited by this paper
• Management of hyperlipidemia in the pediatric population

  2004cited by this paper
• Selectins and monocyte chemotactic peptide as the markers of atherosclerosis activity.

  2004cited by this paper
• Increased red blood cell adhesiveness/aggregation owing to fibrinogen elevation in hypercholesterolaemic patients and the rationale of fibrinogen‐lowering by LDL apheresis

  2004cited by this paper
• Are advanced oxidation protein products potential uremic toxins?

  2003cited by this paper
• Oxidative stress in phagocytes—“The enemy within”

  2002cited by this paper
• First Steps Toward the Establishment of a German Low‐Density Lipoprotein‐Apheresis Registry: Recommendations for the Indication and for Quality Management

  2002cited by this paper
• Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART).

  2002cited by this paper
• Highly effective reduction of C-reactive protein in patients with coronary heart disease by extracorporeal low density lipoprotein apheresis.

  2002cited by this paper
• First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management.

  2002cited by this paper
• Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial.

  2002cited by this paper
• C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis.

  2001cited by this paper
• Acute changes in plasma levels of hepatocyte growth factor during low-density lipoprotein apheresis.

  2001cited by this paper
• Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia.

  2000cited by this paper
• Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis.

  1999cited by this paper
• Hemodialysis prevents liver disease caused by hepatitis C virus: role of hepatocyte growth factor.

  1999cited by this paper
• Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS).

  1999cited by this paper
• LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia.

  1998cited by this paper
• Improvement of coronary vasodilatation capacity through single LDL apheresis.

  1998cited by this paper
• Effects of lipids and lipoproteins on thrombosis and rheology.

  1998cited by this paper
• Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia

  1998cited by this paper
• Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

  1998cited by this paper
• Improvement of myocardial perfusion after low-density lipoprotein apheresis treatment.

  1997cited by this paper
• Effect of Apheresis of Low-Density Lipoprotein on Peripheral Vascular Disease in Hypercholesterolemic Patients with Coronary Artery Disease

  1996cited by this paper
• Decreased susceptibility of low-density lipoproteins to in-vitro oxidation after dextran-sulfate LDL-apheresis treatment.

  1996cited by this paper
• Indications for low-density lipoprotein apheresis.

  1994cited by this paper
• Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood.

  1985cited by this paper
• Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.

  1982cited by this paper

• Lipoprotein apheresis: Current overview and future outlook in clinical practice.

  2025cites this paper
• Lipid Profile and Management of Dyslipidemias in Pregnancy

  2025cites this paper
• Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

  2021cites this paper
• Desialylation of platelet surface glycans enhances platelet adhesion to adsorbent polymers for lipoprotein apheresis

  2020cites this paper
• Relapsing and Progressive Complications of Severe Hypertriglyceridemia: Effective Long-Term Treatment with Double Filtration Plasmapheresis

  2020cites this paper
• Comparison of cytokine changes in three different lipoprotein apheresis systems in an ex vivo whole blood model

  2019cites this paper
• Current insights into the German Lipoprotein Apheresis Registry (GLAR) - Almost 5 years on.

  2017cites this paper
• The impact of citrate concentration on adhesion of platelets and leukocytes to adsorbents in whole blood lipoprotein apheresis

  2017cites this paper
• The German Lipoprotein Apheresis Registry (GLAR) – almost 5 years on

  2017cites this paper
• Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

  2017cites this paper
• Release and cellular origin of extracellular vesicles during circulation of whole blood over adsorbent polymers for lipid apheresis.

  2017cites this paper
• Therapiealgorithmus zur Lipoproteinapherese und PCSK9-Inhibition bei schwerer Hypercholesterinämie oder isolierter Lipoprotein(a)-Hyperlipoproteinämie

  2016cites this paper
• Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels

  2015cites this paper
• Treatment of homozygous familial hypercholesterolemia

  2014cites this paper
• Effects of Atorvastatin on Oxidative Stress Biomarkers and Mitochondrial Morphofunctionality in Hyperfibrinogenemia-Induced Atherogenesis

  2014cites this paper